Jan K Buitelaar1, Timothy E Wilens, Shuyu Zhang, Yu Ning, Peter D Feldman. 1. Department of Psychiatry, Radboud University Nijmegen Medical Centre and Karakter University Centre for Child and Adolescent Psychiatry, Nijmegen, The Netherlands. j.buitelaar@psy.umcn.nl
Abstract
BACKGROUND: This meta-analysis was designed to determine the relationship between reduction of attention-deficit/hyperactivity disorder (ADHD) symptoms and improvement in functioning by examining short-term changes in functional and symptomatic scores in children and adolescents with ADHD. METHODS: Search of atomoxetine's clinical trial database identified four studies involving a symptomatic measure, the ADHD Rating Scale-IV-Parent Version:Investigator-administered and -scored (ADHDRS-IV-Parent:Inv), and a functional measure, the Life Participation Scale for ADHD (LPS). RESULTS: Correlation analysis revealed a moderate-to-strong association between changes in the LPS total versus ADHDRS-IV-Parent:Inv total (r: -.68). The LPS Self-control subscale showed higher correlations than the Happy/Social subscale with the symptomatic measures. Regression analysis also showed high sensitivity for functional measures to changes in symptom severity. Stratified analysis of mean changes in ADHDRS-IV-Parent:Inv scores corresponding to standardized changes in LPS functional scores indicated that a threshold reduction of 16-18 points on the ADHDRS-IV-Parent:Inv total score was needed for functional improvements to become evident. CONCLUSIONS: Subjects' symptomatic improvements appear to be reflected in improvements in their social and behavioral function as measured by the LPS. These initial findings warrant verification by replication with other outcome measures.
RCT Entities:
BACKGROUND: This meta-analysis was designed to determine the relationship between reduction of attention-deficit/hyperactivity disorder (ADHD) symptoms and improvement in functioning by examining short-term changes in functional and symptomatic scores in children and adolescents with ADHD. METHODS: Search of atomoxetine's clinical trial database identified four studies involving a symptomatic measure, the ADHD Rating Scale-IV-Parent Version:Investigator-administered and -scored (ADHDRS-IV-Parent:Inv), and a functional measure, the Life Participation Scale for ADHD (LPS). RESULTS: Correlation analysis revealed a moderate-to-strong association between changes in the LPS total versus ADHDRS-IV-Parent:Inv total (r: -.68). The LPS Self-control subscale showed higher correlations than the Happy/Social subscale with the symptomatic measures. Regression analysis also showed high sensitivity for functional measures to changes in symptom severity. Stratified analysis of mean changes in ADHDRS-IV-Parent:Inv scores corresponding to standardized changes in LPS functional scores indicated that a threshold reduction of 16-18 points on the ADHDRS-IV-Parent:Inv total score was needed for functional improvements to become evident. CONCLUSIONS: Subjects' symptomatic improvements appear to be reflected in improvements in their social and behavioral function as measured by the LPS. These initial findings warrant verification by replication with other outcome measures.
Authors: Eva Loth; Will Spooren; Lindsay M Ham; Maria B Isaac; Caroline Auriche-Benichou; Tobias Banaschewski; Simon Baron-Cohen; Karl Broich; Sven Bölte; Thomas Bourgeron; Tony Charman; David Collier; Fernando de Andres-Trelles; Sarah Durston; Christine Ecker; Andre Elferink; Marion Haberkamp; Robert Hemmings; Mark H Johnson; Emily J H Jones; Omar S Khwaja; Sabine Lenton; Luke Mason; Valentina Mantua; Andreas Meyer-Lindenberg; Michael V Lombardo; Laurence O'Dwyer; Koichi Okamoto; Gahan J Pandina; Luca Pani; Antonio M Persico; Emily Simonoff; Sitra Tauscher-Wisniewski; Jordi Llinares-Garcia; Spiros Vamvakas; Steve Williams; Jan K Buitelaar; Declan G M Murphy Journal: Nat Rev Drug Discov Date: 2016-01 Impact factor: 84.694
Authors: Nicola C Savill; Jan K Buitelaar; Ernie Anand; Kathleen Ann Day; Tamás Treuer; Himanshu P Upadhyaya; David Coghill Journal: CNS Drugs Date: 2015-02 Impact factor: 5.749
Authors: Andrew Lloyd; Paul Hodgkins; Rahul Sasane; Ron Akehurst; Edmund J S Sonuga-Barke; Patrick Fitzgerald; Annabel Nixon; Haim Erder; John Brazier Journal: Patient Date: 2011 Impact factor: 3.883
Authors: Khyati Brahmbhatt; Donald M Hilty; Mina Hah; Jaesu Han; Kathy Angkustsiri; Julie B Schweitzer Journal: J Adolesc Health Date: 2016-05-18 Impact factor: 5.012
Authors: Kevin M Antshel; Teresa M Hargrave; Mihai Simonescu; Prashant Kaul; Kaitlin Hendricks; Stephen V Faraone Journal: BMC Med Date: 2011-06-10 Impact factor: 8.775
Authors: J K Buitelaar; M Casas; A Philipsen; J J S Kooij; J A Ramos-Quiroga; J Dejonckheere; J C van Oene; B Schäuble Journal: Psychol Med Date: 2011-06-01 Impact factor: 7.723